Publikasi Scopus Covid-19 Per 14 Agustus 2024 (559 artikel)

Shiina S.; Gani R.A.; Yokosuka O.; Maruyama H.; Nagamatsu H.; Payawal D.A.; Dokmeci A.K.; Lesmana L.A.; Tanwandee T.; Lau G.; Sarin S.K.; Omata M.
Shiina, Shuichiro (7005392858); Gani, Rino A. (23495930300); Yokosuka, Osamu (7103382578); Maruyama, Hitoshi (56008397600); Nagamatsu, Hiroaki (7006294863); Payawal, Diana Alcantara (7801385732); Dokmeci, A. Kadir (6603374398); Lesmana, Laurentius A. (58379327600); Tanwandee, Tawesak (57042502500); Lau, George (36114075400); Sarin, Shiv Kumar (7102500714); Omata, Masao (36043368300)
7005392858; 23495930300; 7103382578; 56008397600; 7006294863; 7801385732; 6603374398; 58379327600; 57042502500; 36114075400; 7102500714; 36043368300
APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19
2020
Hepatology International
14
6
920
929
9
20
Department of Gastroenterology, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan; Department of Internal Medicine, Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia; Chiba University, Chiba, Japan; Department of Hepatology, Cardinal Santos Medical Center, Manila, Philippines; Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey; Digestive Disease and GI Oncology Center, Medistra, Hospital, University of Indonesia, Jakarta, Indonesia; Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Hong Kong; Liver Disease and Transplant Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China; Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, 110070, India; Department of Gastroenterology, Yamanashi Prefectural Central Hospital, Kofu-city, Yamanashi, Japan; The University of Tokyo, Tokyo, Japan
Shiina S., Department of Gastroenterology, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan; Gani R.A., Department of Internal Medicine, Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia; Yokosuka O., Chiba University, Chiba, Japan; Maruyama H., Department of Gastroenterology, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan; Nagamatsu H., Department of Gastroenterology, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan; Payawal D.A., Department of Hepatology, Cardinal Santos Medical Center, Manila, Philippines; Dokmeci A.K., Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey; Lesmana L.A., Digestive Disease and GI Oncology Center, Medistra, Hospital, University of Indonesia, Jakarta, Indonesia; Tanwandee T., Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Lau G., Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Hong Kong, Liver Disease and Transplant Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China; Sarin S.K., Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, 110070, India; Omata M., Department of Gastroenterology, Yamanashi Prefectural Central Hospital, Kofu-city, Yamanashi, Japan, The University of Tokyo, Tokyo, Japan
Background: COVID-19 has been giving the devastating impact on the current medical care system. There are quite many guidelines on COVID-19, but only a few on the management of hepatocellular carcinoma (HCC) during COVID-19 pandemic. Aims: We develop these recommendations to preserve adequate clinical practice for the management of HCC. Methods: Experts of HCC in the Asia–Pacific region exchanged opinions via webinar, and these recommendations were formed. Results: Close contact should be minimized to reduce possible exposure of both medical staff and patients to the novel coronavirus. To prevent transmission of the virus, meticulous hygiene measures are important. With the decrease in regular medical service, the medical staff may be mobilized to provide COVID-19-related patient care. However, diagnosis and treatment of HCC should not be delayed because of COVID-19 pandemic. The management of HCC should be the same as in non-pandemic circumstances. HCC is highly malignant, thus it is recommended not to delay curative treatment such as surgery and ablation. However, a kind of triage is necessary even among patients with HCC when resources are insufficient for all to be treated. Curative treatments should be periodized and cytoreductive or non-curative treatment such as vascular interventions and systemic therapy may be postponed until it can be performed safely with sufficient resources. For patients with confirmed or suspected to be infected with the novel coronavirus, diagnosis and treatment should be postponed until the virus is eliminated or they are confirmed as not being infected with it. Conclusions: These are collection of measures implemented by front-line medical professionals. We would evolve these recommendations over time as more real-world data becomes available. © 2020, The Author(s).
Aerosol generating procedure; Asian-Pacific; Asymptomatically infected; Chronic liver disease; CT screening for COVID-19; Decision-making; Diagnosis; Facemask; Hospital preparedness; Liver cancer; Personal protective equipment; Surveillance; The novel coronavirus; Treatment
Carcinoma, Hepatocellular; COVID-19; Humans; Liver Neoplasms; immunological antineoplastic agent; protein tyrosine kinase inhibitor; Article; cancer immunotherapy; cancer incidence; cancer mortality; cancer radiotherapy; causal attribution; cause of death; clinical practice; computer assisted tomography; coronavirus disease 2019; disease association; disease severity; drug effect; echography; exposure; human; liver cell carcinoma; liver resection; liver transplantation; medical staff; mortality; nonhuman; nuclear magnetic resonance imaging; pandemic; priority journal; Severe acute respiratory syndrome coronavirus 2; systemic therapy; treatment planning; tumor ablation; virus transmission; complication; liver cell carcinoma; liver tumor; practice guideline
Springer
19360533
33174159
Article
Q1